Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone
This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are comp
| Condition(s) | Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a p |
| Who can participate | Inclusion Criteria: * Age: birth to \< 30 years of age * Diagnosis: \-- Patient with acute leukemia, chronic leukemia, MDS/AML, myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or relapsed/refractory. * Pathology Criteria: \-- Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence * Specimen Criteria: * Sufficient sample available for genomic profiling OR bone marrow aspirate/blood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements) Exclusion Criteria: \- Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence (See Se |
| Ages | 30 Years |
| Sex | All |
| Lead sponsor | Dana-Farber Cancer Institute |
| Locations | Hartford, Connecticut, United States; Portland, Maine, United States; Boston, Massachusetts, United States; Boston, Massachusetts, United States; Lebanon, New Hampshire, United States; Albany, New York, United States (+2 more sites) |
| Start date | 2021-06-11 |
| NCT ID | NCT04968834 |
| Official listing | https://clinicaltrials.gov/study/NCT04968834 |